- $55.15m
- $64.20m
- $0.20m
Brief: Clene Reports Significant Survival Benefit With CNM-Au8 Treatment in ALS EAP Compassionate Use Programs
Brief: Clene Reports Significant Improvement In Vision And Cognition With Cnm-Au8 Treatment
Brief: Clene Reports Significant Improvement In Vision And Cognition With Cnm-Au8® Treatment
U.S. STOCKS ON THE MOVE-Cintas Corp, Carnival, Tri Pointe Homes
U.S. STOCKS ON THE MOVE-Emeren Group, Delta Airlines, Annexon Inc
U.S. STOCKS ON THE MOVE-CarMax, Spotify, Immunovant
Clene down after FDA says ALS drug data insufficient for accelerated approval
US FDA finds Clene's trial data for ALS drug to be insufficient (updated)
Brief: Clene Reports Reduction in Biomarker Plasma Neurofilament Light Levels and Improved Survival With CNM-Au8 Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension
Brief: Clene Provides Update on ALS Clinical Development Meeting With FDA
US FDA finds Clene's trial data for nervous system disorder drug to be insufficient
Clene Inc. expected to post a loss of 9 cents a share - Earnings Preview
Pharvaris up after Wedbush initiates stock coverage with 'outperform' rating
Brief: Clene Says Significant Long-Term Survival Improvement From CNM-Au8 Treatment In Healey ALS Platform Trial Compared To Pro-Act Historical Controls
U.S. STOCKS ON THE MOVE-Oracle, Onto Innovation, Gold miners
U.S. STOCKS ON THE MOVE-e.l.f. Beauty, United States Steel, Copper miners
Clene rises on positive data from ALS therapy study
Brief: Clene Q2 Basic EPS USD -0.29
Clene Inc. reports results for the quarter ended in June - Earnings Summary